PAX6 and hereditary disease: This led Behaegel and colleagues to evaluate the outcomes of an allogeneic HLA-matched allo-CLET for the treatment of aniridia-associated keratopathy in 6 patients with aniridia, a rare genetic disorder due to mutations in the Pax6 gene [29].